Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome

Stopped early · Not applicable

Conditions studied: Maroteaux-Lamy Syndrome

In brief

This is a single center study in which Naglazyme® will be given weekly for two years in patients with Maroteaux-Lamy syndrome, also known as mucopolysaccharide VI (MPS VI), who have previously been treated with an allogeneic transplant.

Key facts

Study ID

NCT02156674

Run by

Masonic Cancer Center, University of Minnesota

People needed

1

Starts

2016-01-26

Expected to finish

2019-12-01

Last updated by the study team

2020-12-23

Who can join

Age: 3 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Mucopolysaccharidosis type VI (MPS VI, Maroteaux-Lamy syndrome) treated with a prior allogeneic transplant >2 years previously
• Persons currently receiving Naglazyme may be accepted into the study
• Age > 2 years
• >10% engrafted based on most recent testing
• Willing to commit to traveling to the University of Minnesota every 6 months
• Written informed consent with parent/guardian consent for children < 18 years of age or persons unable to consent with minor assent if appropriate

You may not qualify if…

• History of cardiac or pulmonary insufficiency or those requiring continuous supplemental oxygen
• Pregnant or breastfeeding
• Any condition that, in the view of the investigator, places the patient at high risk of poor treatment compliance or of not completing the study

Where it is running

• University of Minnesota Medical Center, Fairview — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.